High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - A retrospective evaluation

Bone Marrow Transplantation

Volumn 34, Issue 9, 2004, Pages 781-786

  Demirer, T ^a   Ayli, M ^b   Fen, T ^c   Ozcan, M ^a   Arat, M ^a   Buyukberber, S ^d   Arslan, O ^a   Gurman, G ^a   Akan, H ^a   Ilhan, O ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ANKARA ONCOLOGY HOSPITAL   (Turkey)

^d GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Autologous PBSC transplant; Lymphoma; TMCb

Indexed keywords

ANTINEOPLASTIC AGENT; BILIRUBIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MANNITOL; MELPHALAN; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLADDER DISEASE; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HEPATOMEGALY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; IDIOPATHIC DISEASE; LIVER DISEASE; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SKIN TOXICITY; SURVIVAL TIME; WEIGHT GAIN; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 7944223441     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704672     Document Type: Article

References (32)

1. Sarosy G, Leyland-Jones B, Soochan P et al. The systemic administration of intravenous melphalan. J Clin Oncol 1988; 6: 1768-1782.
2. Wright JC, Golomb FM, Gumport SL et al. Summary of results with triethylenethiophosphoramide. Ann NY Acad Sci 1958; 68: 937-966.
3. Schiffman K, Buckner CD, Maziarz R et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3 261-266.
4. Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651-655.
5. Demirer T, Ilhan O, Mandel NM et al. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow Transplant 2000; 25: 697-703.
6. Demirer T, Uysal VA, Ayli M et al. High-dose thiotepa, melphalan, and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer - a retrospective evaluation. Bone Marrow Transplant 2003; 31: 755-761.
7. Hill R. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-2117.
8. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26: 1063-1070.
9. Weaver CH, Petersen FB, Appelbaum FR et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem cell support in patients with malignant lymphoma. J Clin Oncol 1994; 12: 2559-2566.
10. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
11. Shubart MC, McDonald GB. Gastrointestinal and hepatic complications. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Massachusetts, USA, 1994; pp 454-459.
12. Crawford SW. Critical care and respiratory failure. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Massachusetts, USA, 1994; pp 513-517.
13. Demirer T, Ayli M, Ozcan M et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte-colony stimulating factor (Rh-GSCF): a randomized evaluation of different doses of Rh-GSCF. Br J Haematol 2002; 116: 468-472.
14. Demirer T, Ayli M, Dagli M et al. Influence of post-transplant recombinant human granulocyte-colony stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol 2002; 118 1104-1111.
15. Demirer T, Ihan O, Ayli M et al. Monitoring of peripheral blood CD34 + cell counts on the first day of apheresis is highly predictive for efficient CD34 + cell yield. Therap Apheresis 2002; 6: 384-389.
16. Rowley SD, Bensinger WI, Gooley T et al. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994; 83: 2731-2736.
17. Demirer T, Dagl M, Ilhan O et al. A randomized trial of assessment of efficacy of leukapheresis volumes, 81 vs 121. Bone Marrow Transplant 2002; 29: 893-897.
18. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
19. Gorin NC. Stem cell processing and transplantation. The present models of acute leukemias and non-hodgkin's lymphomas in adults. Turkish J Hematol 1996; 14: 15-21.
20. Press OW, Livingston R, Mortimer J et al. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 1991; 9: 423-432.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Appelbaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total-body irradiation, and marrow transplantation. J Clin Oncol 1987; 5 1340-1347.
23. Petersen FB, Appelbaum FR, Bigelow CL et al. High-dose cytosine arabinoside, total-body irradiation and marrow transplantation for advanced malignant lymphoma. Bone Marrow transplant 1989; 4 483-488.
24. Gutierrez-Delgado F, Holmberg L, Hooper H et al. Auto-logous stem cell transplantation for Hodgkin's disease: busulfan, melphalan, and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 2003; 32: 279-285.
25. Weaver CH, Appelbaum FR, Petersen FB et al. High-dose cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993; 11 1329-1335.
26. Gulati S, Yahalom J, Acaba K et al. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total-body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 1992; 10: 936-941.
27. Srivastava A, Bradstock KF, Szer J et al. Busulfan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant 1993; 12: 323-329.
28. Goldstone AH, McMillan AK, Chopra R et al. High-dose therapy for the treatment of non-Hodgkin's lymphoma. In: Armitage JO, Antman KH (eds). High-Dose Cancer Therapy; Pharmacology, Hematopoietins, Stem Cells. Williams & Wilkins: Baltimore, MD, 1992; pp 662-676.
29. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 1993; 11: 711-740.
30. Wheeler C, Antin JH, Churchill M et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648-654.
31. Horning SJ, Negrin RS, Chao NJ et al. High-dose etoposide regimens and autologous bone marrow transplantation (ABMT) for malignant lymphoma: results in 202 consecutive patients. Proc ASCO (abstract) 1993; 12: 382.
32. Stockerl-Goldstein KE, Horning SF, Negrin RS et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996; 2: 76-81.